LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

Home・Akcijų sąrašas・Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

1.31 -2.96

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.28

Max

1.37

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.4M -40M
Pardavimai	6.2M 45M
Pelno marža	-90.427
Darbuotojai	485
EBITDA	-6M -38M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+75% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-74M 481M
Ankstesnė atidarymo kaina	4.27
Ankstesnė uždarymo kaina	1.31

Naujienos nuotaikos

By Acuity

67%

33%

312 / 346 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

1.13 / N/A Palaikymas ir pasipriešinimas

Pacific Biosciences of California Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-11 22:15; UTC

Įsigijimai, susijungimai, perėmimai

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

2026-05-11 23:46; UTC

Rinkos pokalbiai

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

2026-05-11 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on AI Enthusiasm -- Market Talk

2026-05-11 23:33; UTC

Rinkos pokalbiai

Gold Rises on Possible Position Adjustments -- Market Talk

2026-05-11 22:37; UTC

Rinkos pokalbiai

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

2026-05-11 22:32; UTC

Uždarbis

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

2026-05-11 22:02; UTC

Rinkos pokalbiai

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

2026-05-11 21:49; UTC

Uždarbis

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

2026-05-11 21:42; UTC

Rinkos pokalbiai

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

2026-05-11 21:31; UTC

Įsigijimai, susijungimai, perėmimai

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

2026-05-11 21:23; UTC

Įsigijimai, susijungimai, perėmimai

CSG Systems Sale to NEC Gets CFIUS Clearance

2026-05-11 21:12; UTC

Uždarbis

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

2026-05-11 21:12; UTC

Uždarbis

Ovintiv 1Q Loss/Shr $2.35 >OVV

2026-05-11 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-11 20:44; UTC

Uždarbis

Steris: Board Approves New $1B Shr Repurchase Program >STE

2026-05-11 20:43; UTC

Uždarbis

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

2026-05-11 20:32; UTC

Uždarbis

CleanSpark 2Q Loss/Shr $1.52 >CLSK

2026-05-11 20:32; UTC

Uždarbis

CleanSpark 2Q Rev $136.4M >CLSK

2026-05-11 20:30; UTC

Uždarbis

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

2026-05-11 20:30; UTC

Uždarbis

Steris 4Q Cont Ops EPS $2.24 >STE

2026-05-11 20:30; UTC

Uždarbis

Steris 4Q Rev $1.6B >STE

2026-05-11 20:30; UTC

Uždarbis

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

2026-05-11 20:30; UTC

Uždarbis

Steris 4Q Adj EPS $2.83 >STE

2026-05-11 20:22; UTC

Karštos akcijos

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

2026-05-11 19:37; UTC

Uždarbis

More Bad News at KKR's Private Credit Fund -- Barrons.com

2026-05-11 19:32; UTC

Rinkos pokalbiai

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Akcijų palyginimas

Kainos pokytis

Pacific Biosciences of California Inc Prognozė

Kainos tikslas

By TipRanks

75% į viršų

12 mėnesių prognozė

Vidutinis 2.38 USD 75%

Aukščiausias 3 USD

Žemiausias 1.5 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pacific Biosciences of California Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Pacific Biosciences of California Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.13 / N/APalaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Rinkos nuotaikos

By Acuity

312 / 346 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.